HSGN-218

Class: Synthetic small molecule

Spectrum of activity:	Gram-positive
Details of activity:	Active against Clostridioides difficile, Enterococcus faecium, and Enterococcus faecalis
Description:	Synthetic compound; 100% human colorectal cell viability at 64 ug/ml (>9000x of MIC)
Institute where first reported:	Chemistry Department, Institute for Drug Discovery, Purdue University, West Lafayette, Indiana 47907, United States;  Purdue Institute of Inflammation, Immunology, and Infectious Disease, West Lafayette, Indiana 47907, United States
Year first mentioned:	2020
Development status:	Experimental

Chemical structure(s):
Canonical SMILES:	C1=C(C=CC(=C1)SC(F)(F)F)C(=O)NC2=NN=C(C3=CC(=CC(=C3)Cl)Cl)O2
Isomeric SMILES:	C1=CC(=CC=C1C(=O)NC2=NN=C(O2)C3=CC(=CC(=C3)Cl)Cl)SC(F)(F)F
InChI:	InChI=1S/C16H8Cl2F3N3O2S/c17-10-5-9(6-11(18)7-10)14-23-24-15(26-14)22-13(25)8-1-3-12(4-2-8)27-16(19,20)21/h1-7H,(H,22,24,25)
InChI Key:	YNSLXRYEPGHGRY-UHFFFAOYSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/155235618

External links:
Guide to Pharmacology:	HSGN-218
Main Source:	https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01198
Patent:	WO2020219792A1